Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Immunogenicity and safety of yellow fever vaccine in HIV-1-infected patients.

Colin de Verdiere N, Durier C, Samri A, Meiffredy V, Launay O, Matheron S, Mercier-Delarue S, Even S, Aboulker JP, Molina JM, Autran B, Simon F; ANRS EP46 NOVAA Group.

AIDS. 2018 Oct 23;32(16):2291-2299. doi: 10.1097/QAD.0000000000001963.

PMID:
30096071
2.

Screening test for neutralizing antibodies against yellow fever virus, based on a flavivirus pseudotype.

Mercier-Delarue S, Durier C, Colin de Verdière N, Poveda JD, Meiffrédy V, Fernandez Garcia MD, Lastère S, Césaire R, Manuggera JC, Molina JM, Amara A, Simon F.

PLoS One. 2017 May 31;12(5):e0177882. doi: 10.1371/journal.pone.0177882. eCollection 2017.

3.

Effect of two injections of non-adjuvanted influenza A H1N1pdm2009 vaccine in renal transplant recipients: INSERM C09-32 TRANSFLUVAC trial.

Le Corre N, Thibault F, Pouteil Noble C, Meiffrédy V, Daoud S, Cahen R, Charreau I, Bottigioli D, Dollinger C, Aboulker JP, Autran B, Morelon E, Barrou B.

Vaccine. 2012 Dec 14;30(52):7522-8. doi: 10.1016/j.vaccine.2012.10.047. Epub 2012 Oct 25.

PMID:
23103195
4.

Hyperlactataemia in HIV-infected subjects initiating antiretroviral therapy in a large randomized study (a substudy of the INITIO trial).

Feeney ER, Chazallon C, O'Brien N, Meiffrédy V, Goodall RL, Aboulker JP, Cooper DA, Yeni P, Mallon PW; INITIO Trial International Co-ordinating Committee.

HIV Med. 2011 Nov;12(10):602-9. doi: 10.1111/j.1468-1293.2011.00934.x. Epub 2011 May 22.

5.

Incidence and risk factors of thrombocytopenia in patients receiving intermittent antiretroviral therapy: a substudy of the ANRS 106-window trial.

Bouldouyre MA, Charreau I, Marchou B, Tangre P, Katlama C, Morlat P, Meiffredy V, Vittecoq D, Bierling P, Aboulker JP, Molina JM; ANRS 106 Study Group.

J Acquir Immune Defic Syndr. 2009 Dec;52(5):531-7. doi: 10.1097/QAI.0b013e3181be73e3.

PMID:
19855285
6.

Interruption of antiretroviral therapy initiated during primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 Randomized Study.

Goujard C, Marcellin F, Hendel-Chavez H, Burgard M, Meiffrédy V, Venet A, Rouzioux C, Taoufik Y, El Habib R, Beumont-Mauviel M, Aboulker JP, Lévy Y, Delfraissy JF; PRIMOVAC-ANRS 095 Study Group.

AIDS Res Hum Retroviruses. 2007 Sep;23(9):1105-13.

PMID:
17919105
7.

Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial.

INITIO Trial International Co-ordinating Committee, Yeni P, Cooper DA, Aboulker JP, Babiker AG, Carey D, Darbyshire JH, Floridia M, Girard PM, Goodall RL, Hooker MH, Mijch A, Meiffredy V, Salzberger B.

Lancet. 2006 Jul 22;368(9532):287-98.

PMID:
16860698
8.

Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults.

Durier C, Launay O, Meiffrédy V, Saïdi Y, Salmon D, Lévy Y, Guillet JG, Pialoux G, Aboulker JP.

AIDS. 2006 Apr 24;20(7):1039-49.

PMID:
16603857
9.

Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals.

Lévy Y, Durier C, Lascaux AS, Meiffrédy V, Gahéry-Ségard H, Goujard C, Rouzioux C, Resch M, Guillet JG, Kazatchkine M, Delfraissy JF, Aboulker JP; ANRS 093 Study Group.

AIDS. 2006 Feb 14;20(3):405-13.

PMID:
16439874
10.

Experience using MedDRA for global events coding in HIV clinical trials.

Tonéatti C, Saïdi Y, Meiffrédy V, Tangre P, Harel M, Eliette V, Dormont J, Pierre Aboulker J.

Contemp Clin Trials. 2006 Feb;27(1):13-22. Epub 2005 Nov 8.

PMID:
16288902
11.

Genotypic resistance analyses in nucleoside-pretreated patients failing an indinavir containing regimen: results from a randomized comparative trial: (Novavir ANRS 073).

Descamps D, Joly V, Flandre P, Peytavin G, Meiffrédy V, Delarue S, Lastère S, Aboulker JP, Yeni P, Brun-Vézinet F.

J Clin Virol. 2005 Jun;33(2):99-103.

PMID:
15911424
12.

Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients.

Lévy Y, Gahéry-Ségard H, Durier C, Lascaux AS, Goujard C, Meiffrédy V, Rouzioux C, El Habib R, Beumont-Mauviel M, Guillet JG, Delfraissy JF, Aboulker JP; ANRS 093 Study Group.

AIDS. 2005 Feb 18;19(3):279-86.

PMID:
15718838
13.

A survival method to estimate the time to occurrence of mutations: an application to thymidine analogue mutations in HIV-1-infected patients.

Flandre P, Descamps D, Joly V, Meiffredy V, Tamalet C, Izopet J, Brun-Vezinet F.

J Infect Dis. 2004 Mar 1;189(5):862-70. Epub 2004 Feb 10.

PMID:
14976604
14.

Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to initial regimen received.

Flandre P, Descamps D, Joly V, Meiffrédy V, Tamalet C, Izopet J, Aboulker JP, Brun-Vézinet F.

Antivir Ther. 2003 Feb;8(1):65-72.

PMID:
12713066
15.

Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine or stavudine, each in combination with lamivudine and indinavir.

Descamps D, Flandre P, Joly V, Meiffrédy V, Peytavin G, Izopet J, Tamalet C, Zeng AF, Harel M, Lastère S, Aboulker JP, Yéni P, Brun-Vézinet F; NOVAVIR (ANRS 073) Study Group.

J Acquir Immune Defic Syndr. 2002 Dec 15;31(5):464-71. Erratum in: J Acquir Immune Defic Syndr. 2003 Jan;32(1):116..

PMID:
12473833
16.

Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial.

Joly V, Flandre P, Meiffredy V, Leturque N, Harel M, Aboulker JP, Yeni P.

AIDS. 2002 Dec 6;16(18):2447-54.

PMID:
12461419
17.

Adherence to antiretroviral therapy and outcomes in HIV-infected patients enrolled in an induction/maintenance randomized trial.

Flandre P, Peytavin G, Meiffredy V, Saidi Y, Descamps D, Delagnes M, Brun-Vézinet F, Raffi F; Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team.

Antivir Ther. 2002 Jun;7(2):113-21.

PMID:
12212923
18.

Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial).

Joly V, Flandre P, Meiffredy V, Brun-Vezinet F, Gastaut JA, Goujard C, Remy G, Descamps D, Ruffault A, Certain A, Aboulker JP, Yeni P; Novavir Study Group.

Antimicrob Agents Chemother. 2002 Jun;46(6):1906-13.

19.

Final analysis of the Trilège induction-maintenance trial: results at 18 months.

Flandre P, Raffi F, Descamps D, Calvez V, Peytavin G, Meiffredy V, Harel M, Hazebrouck S, Pialoux G, Aboulker JP, Brun Vezinet F.

AIDS. 2002 Mar 8;16(4):561-8.

PMID:
11872999
20.

Adverse reactions to cotrimoxazole in HIV-infected patients: predictive factors and subsequent HIV disease progression.

Rabaud C, Charreau I, Izard S, Raffi F, Meiffredy V, Leport C, Guillemin F, Yeni P, Aboulker JP; Delta trial group.

Scand J Infect Dis. 2001;33(10):759-64.

PMID:
11728044
21.

CD4 T cell recovery is slower in patients experiencing viral load rebounds during HAART.

Scott-Algara D, Aboulker JP, Durier C, Badell E, Marcellin F, Prud'homme M, Jouanne C, Meiffredy V, Brun-Vezinet F, Pialoux G, Raffi F; ANRS-072 Trial Group.

Clin Exp Immunol. 2001 Nov;126(2):295-303.

22.

Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).

Descamps D, Flandre P, Calvez V, Peytavin G, Meiffredy V, Collin G, Delaugerre C, Robert-Delmas S, Bazin B, Aboulker JP, Pialoux G, Raffi F, Brun-Vézinet F.

JAMA. 2000 Jan 12;283(2):205-11. Erratum in: JAMA 2000 Sep 27;284(12):1518.

PMID:
10634336
23.

Supplemental Content

Loading ...
Support Center